Introduction
Erythroderma is a severe dermatological condition, which may result from different causes, including cutaneous T-cell lymphoma (CTCL), especially Sézary syndrome (SS), and several erythrodermic inflammatory diseases (EID), mostly psoriasis, drug-eruptions or atopic dermatitis (Akhyani et al., 2005; Pal and Haroon, 1998; Rym et al., 2005) . In the clinical setting of erythroderma, the identification of an underlying cause is difficult in practice, since clinical and histopathological aspects are most often not enough specific. It is necessary to differentiate benign EID from SS, which is an agressive lymphoma that requires an early and appropriate management (Willemze et al., 2005) . SS is characterized by the presence of a malignant CD4 + CD45RO + T-cell clone that localizes in both the blood and skin. In SS, cutaneous and circulating malignant cells can be roughly identified by morphological analyzes. Circulating Sezary cells however are not specific for the diagnosis of SS (Vonderheid et al., 1985) and histopathologically, atypical epidermotropic T-cells, when present, are sometimes difficult to identify in skin biopsies. The identification of a monoclonal T-cell population can provide diagnostic informations (Curco et al., 1997; Gorochov et al., 1995; Guitart and Kaul, 1999; Witzens et al., 1997; Wood et al., 1994) , which, however, are not fully specific (Delfau-Larue et al., 2000) . Besides the lack of CD26 expression (Bernengo et al., 2001; Jones et al., 2001; Scala et al., 2002) and CD7 (Rappl et al., 2001) , we have described new cell surface markers of malignant Sézary cells (Bagot et al., 2001; Huet et al., 2006) . Among them, CD158k/KIR3DL2, a killer immunoglobulin-like receptor normally expressed by minor subsets of circulating T CD8 + lymphocytes and natural killer (NK) cells (Moretta et al., 1997) , readily allows the identification of the malignant Tcells in the blood of SS patients (Ortonne et al., 2006; Poszepczynska-Guigne et al., 2004) . (Mao et al., 2004; Mao et al., 2003) , NAV3 gene deletion (Karenko et al., 2005) and abnormal expression of various markers at the transcript and/or protein level, such as Twist, and EphA4 (Kari et al., 2003; Nebozhyn et al., 2006) . Among them, T-plastin is a member of the Fimbrins/plastins family, which are highly conserved actin-bundling proteins. T-plastin is not expressed by normal lymphocytes under physiological conditions and was therefore proposed as a specific molecular marker for neoplastic lymphocytes in SS, but, to the best of our knowledge, was not investigated in lesional skin (Su et al., 2003) .
Importantly, only few studies to date have focused on cutaneous samples, so that a specific marker for SS in skin biopsies is still lacking. Although KIR3DL2/CD158k actually delineates the malignant clonal T-cell population in SS (Bagot et al., 2001; Ortonne et al., 2006; Poszepczynska-Guigne et al., 2004) and is expressed at the protein level by lymphocytes in erythrodermic skin of patients with SS , it is not known whether it may help for the diagnosis of erythroderma in skin biopsies. To address this issue, we analyzed the expression of CD158k/KIR3DL2 at both protein and transcript levels in a panel of skin biopsies from patients with erythroderma from various causes, and we compared the results obtained in SS versus benign EID. 
Results

Immunohistochemistry with AZ158 moAb did not clearly discriminate between SS and benign EID
We observed a subepidermal band-like or mostly perivascular lymphocytic infiltrate in all 40 skin samples from the SS and the EID groups, associated with epidermotropic lymphocytes in 85%. The density of dermal T-cell infiltrates was categorized as +, ++ and +++ in 0 (0%), 8 (57%) and 6 (43%) samples from the SS group, respectively, and in 11 (42%), 12 (46%) and 3 (12%) samples from the EID group, respectively. This indicated a higher lymphocytic infiltration in SS, as shown in the cutaneous sample of patient 8 in Figure   1c . As previously reported , immunohistochemistry with AZ158 moAb was positive in all skin biopsies from patients with SS (Figure 1e ), in agreement with CD158k/KIR3DL2 expression. However, with AZ158 moAb, we also found positive cells in 17 biopsies of the EID group (65%), as shown in figure 1f , showing representative sections of a patient with erythrodermic psoriasis. Mean AZ158/CD3 ratios were similar in both groups in the epidermis. However, in EID we found a lower staining with AZ158 moAb in the dermis, with 33% of SS samples versus 74% of EID samples showing a AZ158/CD3 ratio <25%, (Student's t test: P = 0.0045). SS displayed lower CD8/CD3 ratios in both the epidermis and the dermis. Indeed, the mean CD8/CD3 ratio was 12% in SS versus 38 % in EID (Student's t test: P = 0.003) in the epidermis. In the dermis, semi-quantitative evaluation revealed that 83% of SS versus 38% of EID samples had a CD8/CD3 ratio <25% (Student's t test: P = 0.004). This latter finding is in agreement with the preferential intra-epidermal localization of malignant CD4 + lymphocytes in epidermotropic CTCL such as SS and mycosis fungoides, whereas many reactional CD8 + lymphocytes are present in the dermis Bagot et al., 1992; Ortonne et al., 2003) . In addition, in all investigated cases, we did not find CD56 + lymphocytes (data not shown), indicating that NK cells were not predominant within the infiltrates. Altogether, these results indicated that a higher T-cell infiltration was present in SS than in EID skin samples, and that differential diagnosis between SS and EID can not be done reliably using immunohistochemistry with AZ158moAb on frozen skin sections.
CD158k/KIR3DL2 transcripts were significantly overexpressed in SS versus benign EID skin samples
Using conventional RT-PCR CD158k/KIR3DL2 transcripts were readily detected in all but one biopsies from the SS group (89%) whereas significant expression of CD158k/KIR3DL2 mRNA could not be evidenced in any sample from the EID group.
Representative results from conventional RT-PCR are shown in Figure 2 . Using this technique, a distinct bright band could be visualized on agarose gel electrophoresis in 8/9
biopsies from the SS group (Figure 2b middle Using quantitative RT-PCR, CD3 mRNA expression was detected in both SS and EID skin samples, indicating the presence of a significant subset of T lymphocytes within the cutaneous infiltrate in both groups (Fig. 3a , left panel). We found a slight CD3 transcript over-expression in SS samples (Mann-Whitney's test: P=0.0133), in agreement with results of morphological analyzes indicating that T-cell infiltration was higher in the SS group. Using quantitative RT-PCR, we found, with a different set of primers specifically designed for the study (Table S2 , lower part), that CD158k/KIR3DL2 mRNA were readily detected in all but 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F  o  r  R  e  v  i  e  w  O  n  l  y   7 one SS skin samples, with a significant over-expression when compared to samples from the EID group (Mann-Whitney's test: P<0.0001), as shown in figure 3a, middle panel. In EID skin samples, CD158k/KIR3DL2 mRNA appeared to be either undetectable (n = 6, 60%) or expressed at very low levels (n = 4, 40%) as for one sample from the SS group (patient 7, Fig.   3b , left panel) so that quantification was considered inappropriate, due to the presence of non specific products on control agarose gel electrophoresis. CD158e/KIR3DL1 transcripts were undetectable in both the SS and the EID groups (data not shown). To avoid a possible misinterpretation related to the higher T-cell infiltration found in SS skin samples, we also evaluated the CD158k/CD3 ratio of relative mRNA copy number, which remained significantly higher in the SS versus the EID group (Mann-Whithney's test: P=0.0003). 
T-plastin transcripts expression was not significantly higher in SS versus benign EID skin samples
T-plastin, a member of the fimbrin/plastin family normally expressed at low levels by nonhaematopoietic mesenchymal and epithelial tissues (Lin et al., 1993) , has been recently shown to delineate circulating malignant Sézary cells (Su et al., 2003) . Although T-plastin is expected to be expressed in normal skin, we sought to verify whether it might be overexpressed in erythrodermic skin of SS patients, due to infiltration of T-plastin expressing neoplastic lymphocytes. Using quantitative RT-PCR, we found that T-plastin transcripts were detected at similar levels in cutaneous samples from the SS and the EID group, as shown in Figure 3a , right panel (Mann-Whitney's test: P = 0.8421). The T-plastin/CD3 relative mRNA copy number ratio appeared to be slightly more elevated in the EID group, but the difference was not statistically significant (Mann-Whitney's test: P = 0.02). These results suggest that, contrasting with CD158k, T-plastin is not a reliable molecular marker for the diagnosis of SS in skin biopsies. In the present study, we obtained in some skin samples conflicting results with immunohistochemistry and RT-PCR regarding CD158k/KIR3DL2 expression. Indeed, immunoreactivity with AZ158 moAb was found within lymphocytic infiltrates of a proportion of EID, while we could not detect significant expression of CD158k/KIR3DL2 transcript in the same skin specimen. One hypothesis is that non neoplastic reactional lymphocytes in erythrodermic skin from patients with benign dermatoses may express alternative splicing variant of CD158k/KIR3DL2, lacking one or both of the exonic domains of primer hybridization. To address this issue, we designed three additional sets of primers, allowing amplification of three distinct CD158k/KIR3DL2 transcript segment located within exon 3 -5, 4 -9, and 8 -9 (Table S2, Figure 4 ). Using all three sets of primers, negative results were constantly obtained in all four EID samples analyzed, as well as in normal skin used as a negative control. By contrast, we could detect a distinct band at the expected size on agarose gel electrophoresis in both skin samples from patient 3 and Sezary cell line OGU, used as a positive control. These findings indicate that the negative results obtained with both conventional and quantitative RT-PCR regarding CD158k/KIR3DL2 mRNA expression in the EID group were not due to alternative splicing of CD158k/KIR3DL2 transcripts. the diagnostic value of this marker for the diagnosis of erythroderma in skin specimen has never been studied. In the present study, expression of CD158k/KIR3DL2 was analyzed at both protein product and transcriptional levels in a series of frozen skin biopsies from patients with erythroderma. Since AZ158 moAb, which recognizes both CD158k/KIR3DL2 and CD158e/KIR3DL1, was used for immunohistochemical procedures, both transcripts were analyzed by molecular studies on the same skin specimen. Unexpectedly, we found that, although constantly positive in SS samples, immunohistochemistry using AZ158 moAb in frozen skin sections was not enough discriminant between SS and EID. Immunoreactivity to AZ158 moAb was actually demonstrated in a significant proportion of benign inflammatory erythrodermas, suggesting that CD158k/KIR3DL2 + and/or CD158e/KIR3DL1 + cells are recruited in the skin in erythrodemic inflammatory conditions. As NK lymphocytes and minor subsets of CD8+ T-cells may express KIRs under physiological conditions (Moretta et al., 1997) , it is tempting to hypothesize that positive cells in the EID group corresponded to normal lymphocytes expressing CD158k/KIR3DL2 and/or CD158e/KIR3DL1. The higher CD8/CD3 ratios and the constant negativity of CD56 staining obtained in the EID group (Lin et al., 1993) . As we found evidences that SS had a higher T-cell infiltration than EID, CD158k/KIR3DL2 and Tplastin relative mRNA expression was normalized to CD3, which still showed a significant overexpression of the former in the SS group. In this series, using specific transcripts detection and quantification, CD158k/KIR3DL2 thus appeared to be a unique molecular marker of SS in the skin, contrasting with immunohistochemistry with AZ158 moAb and Tplastin mRNA quantification, which were not enough discriminant between SS and benign EID. Noted that, two patients from this series were evaluated at the stage of partial remission under treatment. One partially responded to interferon with persistent erythemato-squamous plaques whereas the other one had advanced disease and was evaluated after he was placed under systemic PCT. In skin biopsies of these patients, CD158k/KIR3DL2 expression could be demonstrated using AZ158 immunostaining and RT-PCR assays, whereas no or few Sézary cells could be detected in the blood. This finding suggested that although malignant Tcells could not be detected in the blood, viable tumor cells were still present in the skin. In light of these results, it is tempting to speculate that the skin may represent a sanctuary site for neoplastic cells in patients placed under systemic therapies. In agreement with this hypothesis, Assaf et al. have recently reported a patient with erythrodermic SS who turned into plaque stage disease and then high grade T-cell lymphoma under treatment with extracorporeal photopheresis, whereas clearance of circulating Sézary cells was obtained (Assaf et al., 2004) . with this latter hypothesis, the heterogeneous expression of some KIRs within an identical Tcell clone has been previously reported in normal T-cells (Vely et al., 2001) , and, similarly, we have reported heterogeneous expression of CD158k/KIR3DL2 within a malignant Sézary T-cell clone (Ortonne et al., 2006) . These findings indeed indicate that KIRs expression in Tcells can occur at a mature stage of differentiation, after TCR rearrangements, and further suggest that KIR expression may be positively and/or negatively regulated in these cells.
CD158k/KIR3DL2 alternatively spliced variants were not detected in skin samples of benign EID
In conclusion, the detection of significant levels of CD158k/KIR3DL2 transcript using quantitative RT-PCR in erythrodermic skin allows diagnosis of SS, even in very early stages of the disease, and represents a reliable marker of the disease in skin samples. This molecular marker can be easily used in routine practice to make differential diagnosis between erythrodermic benign inflammatory dermatoses and SS, which requires early and specific management. 
Materials and methods
Patients selection, control cases and cells
Thirteen frozen biopsy samples from 10 patients with SS were retrieved from the files of the Department of Pathology of our institution (Hôpital Henri Mondor, Créteil). The clinical features of the patients with SS are shown in Table 1 . There were 4 females and 6 males, with a median age of 71 years (range 61 -79 years). In these patients, diagnosis of SS was made according to the current WHO-EORTC classification (Willemze et al., 2005) and following the criteria defined by Russell-Jones et al (Russell-Jones, 2005) . Among these criteria, a T-cell clone could be evidenced in both the skin and blood of all patients from the SS group. In addition, CD158k/KIR3DL2 expression by peripheral blood lymphocytes could be demonstrated in 3 patients out of the SS group (patients 1, 2 and 3, Table 1 ) using flow cytometry studies, as previously described (Ortonne et al., 2006; Poszepczynska-Guigne et al., 2004) . Two SS patients were investigated at the time of partial remission, with no or few circulating Sézary cells: patient 4 had slight persistent erythroderma without circulating Sézary cells after a first round of polychemotherapy (PCT) and patient 6 had persistant erythematous plaques under interferon treatment. In the former, PCT was introduced because the patient had stage IV progressive disease with multiple large adenopathies.
As control samples, we selected skin biopsies from 26 erythrodermic patients (10 females and 16 males, mean age, 67 years), with a diagnosis of non-lymphomatous, benign EID: erythrodermic psoriasis (n=8), drug eruption (n=10 including one with acute generalized exanthematic pustulosis and three with drug-induced hypersensitivity syndrome), eczema (n=3), pityriasis rubra pilaris (n=1), myelodysplastic syndrome (n=1), primary 
Immunohistochemistry and evaluation of the CD8/CD3 and AZ158(CD158k/e)/CD3 ratios
For immunostaining procedure, 5 micrometer-thick frozen sections were applied on Superfrost plus slides (CML, Angers, France), overnight air dried and fixed in aceton for ten minutes before storing at -20°C. Slides were post-fixed in aceton for 5 minutes and air dried before use. The immunostaining procedure was performed after rehydratation in Tris/NaCl buffer. CD158k/KIR3DL2 expression was analyzed using the purified IgG2a AZ158 monoclonal antibody (moAb) (Innate Pharma, Marseille, France), which also recognizes the monomeric receptor CD158e/KIR3DL1 (Parolini et al., 2002) . The anti-CD3, -CD4, -CD8, and -CD56 moAbs were purchased from DAKO (DAKO SA, Glostrup, Denmark). All primary moAbs were used at a 1:50 dilution. We used an incubation period of 4 hours for AZ158 and 1 hour for all other primary moAbs, at room temperature. The staining was was counted on the total epidermal length. In the dermis, a semi-quantitative analysis was done, in which we categorized the CD4/CD3, CD8/CD3 and AZ158/CD3 ratios into 4 groups: 1 (0-25%), 2 (>25-50%), 3 (>50-75%) or 4 (>75%-100%).
RT-PCR amplification of CD3, CD158k/KIR3DL2, CD158e/KIR3DL1 and T-plastin transcripts
Molecular studies were performed on the same frozen skin sample used for immunohistochemistry in 9 specimens from 8 patients out of the SS group and in 10 specimens out of the EID group. As controls for molecular studies, we used total mRNA extracted from normal skin and NK lymphocytes of healthy donors and from the Sézary cell lines Pno (Poszepczynska et al., 2000) , previously established in our laboratory, and OGU, recently developped (Marie-Cardine et al., 2007) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Amplification of CD158k, CD158e and -actin transcripts using conventional polymerase chain reaction (PCR) was performed as previously described (Uhrberg et al., 1997) , with amplification conditions as following: initial denaturation at 95°C for 2 min; then 60 s at 62°C for hybridization, 45 s at 72°C for elongation and 60 s at 94°C for next steps denaturation, for the first five cycles, and then 45 s at 60°C, 45 s at 72°C and 30 s at 94°C for 30 cycles. We used previously reported primers for CD158k/KIR3DL2 and CD158e/KIR3DL1 (Uhrberg et al., 1997) , as well as for -actin (Ju et al., 1999) , used as a positive control. Regarding CD158k/KIR3DL2, additional sets of primers were used, in order to search for alternatively spliced transcripts, allowing amplification of mRNA segments located with exons 3-5, 4-9, and 8-9, as shown in Figure 1 . The sequence and positions of all primers used for conventional PCR are indicated in Table S2 (upper part).
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Quantitative PCR reactions for CD3 (delta chain), CD158k, CD158e and T-plastin were performed in a LightCycler 2.0 System (Roche Diagnostics, Meylan, France) using a SYBR Green PCR kit from Roche Diagnostics (Meylan, France). Melting curves and agarose gel electrophoresis established the purity of the amplified product. Normalization was achieved by quantification of the mRNA expression of the SF3A1 gene, encoding for the 120 kDa subunit of the splicing factor 3a (Tanackovic and Kramer, 2005) , chosen as control housekeeping gene (Szabo et al., 2004) for its stable expression in lymphocytes, as previously described (Mesel-Lemoine et al., 2006) . PCR samples contained 4 mM MgCL 2 , 0.4µM of each primer, and amplification cycling conditions were as following: 94°C for denaturation, (Gibson et al., 1996) . As calibrator samples, we used PBMC of healthy control donors activated for 1 hour with phorbol ester and ionomycin (5ng/ml and 1ng/ml, respectively) for CD3, CD158k, CD158e, and a liver specimen for T-plastin. All PCR conditions were adjusted in order to obtain equivalent optimal amplification efficiency between the different assays. By using the obtained linear graphs, the differences in C t values were determined for each sample and were expressed as relative percentage of mRNA present in the calibrator sample, according to the C t method, after adjustment of PCR efficiency with the Light Cycler software 4.0 (Roche). Quantification was considered to be unreliable when the presence of non specific products was detected on the control agarose gel. In these cases, the relative percentage of transcripts was arbitrarily set as .1. All PCR experiment were done in duplicate. The sequence and positions of primers used for quantitative PCR are indicated in Table S2 (lower part).
T-cell clonality analysis
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